European Organisation For Research And Treatment Of Cancer - Eortc

This phase 3 trial tests whether the drug tebentafusp can prevent uveal melanoma from coming back in high-risk patients after their initial treatment. About 290 people with a specific genetic marker (HLA-A*02:01) will either receive weekly infusions of tebentafusp or be observed …

This study tests a drug called 177Lu-DOTATATE for people with recurrent meningioma, a type of brain tumor that has come back after surgery or radiation. The drug delivers radiation directly to tumor cells by targeting a protein found on these tumors. About 136 adults will be rand…

This study tests whether adding a second round of radiation to the chemotherapy drug lomustine helps people with recurrent glioblastoma live longer. About 411 adults whose brain tumor has returned after standard treatment will be randomly assigned to get lomustine alone or lomust…

This study tests a radioactive drug, 177Lu-PSMA-617, in people with advanced kidney cancer that has spread and worsened despite standard treatments like immunotherapy and targeted therapy. The drug targets a protein called PSMA found on kidney cancer cells, delivering radiation d…

This study tests whether adding precise, high-dose radiation (SABR) to the standard immunotherapy drug pembrolizumab can help people with head and neck cancer that has spread to 1-5 spots in the body. About 200 adults with a specific type of head and neck cancer will be randomly …

This phase 3 trial tests whether the drug vorasidenib can delay tumor progression in people with IDH-mutant grade 2 or 3 astrocytoma after they finish initial chemoradiotherapy. About 468 participants will receive either vorasidenib or a placebo daily. The main goal is to see if …

This study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study is for men with metastatic hormone-sensitive prostate cancer who have already been on hormone therapy for 6-12 months and have very low PSA levels. It compares two approaches: stopping and restarting treatment based on PSA levels (intermittent) versus staying on treatm…

SPECTA is a large research platform that collects tumor samples, genetic data, and patient information from nearly 5,000 people with all types of cancer. The goal is to help scientists better understand cancer biology and find new ways to match patients with the right clinical tr…

This study is collecting data from 1,650 people with various brain tumors to see if the updated 2021 WHO classification system helps doctors group patients more accurately and choose better treatments. Researchers will track responses to therapy, survival, and tumor features over…